8-K: Praxis Precision Medicines Halts Essential Tremor Study, Focuses on Other Pipeline Programs

Praxis Precision Medicines stops Study 1 of its Essential3 program for essential tremor due to futility, but will continue both studies to completion, while advancing other CNS therapies and reporting a strong cash position.

Summary

• Praxis Precision Medicines announced that the IDMC recommended stopping Study 1 of the Essential3 program for ulixacaltamide in essential tremor due to futility based on an interim analysis.
• Despite this recommendation, Praxis will continue both Study 1 and Study 2 to completion, with topline results expected in the third quarter of 2025.
• The company is focusing on other development programs, including vormatrigine for focal onset seizures (FOS) and generalized epilepsy, and relutrigine for developmental epilepsies and encephalopathies (DEEs).
• Topline results from the RADIANT study are expected by mid-year 2025, and POWER1 study results are anticipated in the second half of 2025.
• The EMERALD study for DEEs is expected to begin by mid-year 2025.
• Elsunersen's EMBRAVE3 study for early-seizure-onset SCN2A-DEE is anticipated to start enrolling patients by mid-year 2025.
• Praxis had $469.5 million in cash, cash equivalents, and marketable securities as of December 31, 2024, which is expected to fund operations into 2028.
• The company recognized $8.6 million in collaboration revenue for the year ended December 31, 2024, related to its agreement with UCB.
• Research and development expenses were $152.4 million for the year ended December 31, 2024.
• Praxis reported a net loss of $182.8 million for the year ended December 31, 2024.

Sentiment

Score: 5

Explanation: The news is mixed. The failure of the Essential Tremor study is a significant setback, but the company has a strong cash position and is progressing other pipeline programs. The sentiment is neutral, reflecting both positive and negative developments.

Positives

• Praxis has a strong cash position of $469.5 million as of December 31, 2024, which is expected to fund operations into 2028.
• UCB exercised its option to in-license a KCNT1 small molecule development candidate, providing Praxis with an option exercise fee and potential future milestone payments up to $100 million, plus royalties.
• The company is progressing multiple other programs, including vormatrigine and relutrigine, with several topline readouts expected in 2025 and 2026.
• Praxis received Rare Pediatric Disease Designation (RPDD) from the FDA for relutrigine for Dravet Syndrome, adding to previous RPDDs for SCN2A and SCN8A DEEs.

Negatives

• The IDMC recommended stopping Study 1 of the Essential3 program for ulixacaltamide in essential tremor due to futility, indicating the drug is unlikely to meet the primary efficacy endpoint.
• Praxis incurred a net loss of $182.8 million for the year ended December 31, 2024, compared to a net loss of $123.3 million for the year ended December 31, 2023.
• Research and development expenses increased significantly to $152.4 million for the year ended December 31, 2024, compared to $86.8 million for the year ended December 31, 2023.

Risks

• The failure of Study 1 of the Essential3 program raises concerns about the potential of ulixacaltamide for treating essential tremor.
• Clinical trials are inherently uncertain, and preliminary analyses may differ materially from final data.
• Regulatory approvals are not guaranteed, and delays or rejections could impact the company's pipeline.
• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to numerous risks and uncertainties.

Future Outlook

Praxis expects to continue advancing its pipeline programs, with multiple topline readouts expected in 2025 and 2026. The company believes its current cash position is sufficient to fund operations into 2028.

Management Comments

• 'We are disappointed with and surprised by the outcome of the interim analysis for Study 1,' said Marcio Souza, president and chief executive officer of Praxis.
• 'Following the advice of the committee, we will explore different analysis methods for the final dataset, which is expected in the third quarter of 2025.'
• 'We remain focused on delivering on major near-term milestones in our other development programs, including the topline results from the RADIANT and POWER1 studies in focal onset seizures (FOS) and generalized epilepsy with vormatrigine, and the initiation of our EMERALD registrational study of relutrigine in developmental epilepsies and encephalopathies (DEEs) by mid-year 2025.'
• 'We maintain a robust financial position that supports our continued investment in this exciting pipeline.'

Industry Context

The announcement reflects the high-risk nature of pharmaceutical development, particularly in CNS disorders. While the failure of the Essential3 study is a setback, Praxis is pivoting to focus on other promising programs in its pipeline, aligning with a common strategy in the biopharmaceutical industry to diversify risk and pursue multiple therapeutic avenues.

Comparison to Industry Standards

• The failure of the Essential3 program's interim analysis is not uncommon in the biopharmaceutical industry, where many clinical trials fail to meet their primary endpoints.
• Companies like Biohaven, which also focused on neurological disorders, have faced similar setbacks in specific programs while continuing to advance other assets.
• Praxis's cash runway into 2028 is relatively strong compared to many other clinical-stage biopharmaceutical companies, providing financial flexibility to pursue its pipeline programs.
• The collaboration with UCB is similar to other partnerships in the industry, where larger pharmaceutical companies in-license promising assets from smaller biotechs.

Stakeholder Impact

• Shareholders may react negatively to the failure of Study 1 of the Essential3 program.
• Employees may experience uncertainty due to the program's discontinuation, but the company's focus on other programs could mitigate this.
• Patients with essential tremor may be disappointed by the setback in the development of ulixacaltamide.
• The company's strong cash position provides stability for its suppliers and creditors.

Next Steps

• Continue Study 1 and Study 2 of the Essential3 program to completion, with topline results expected in Q3 2025.
• Report topline results from the RADIANT study by mid-year 2025.
• Report topline results from the POWER1 study in the second half of 2025.
• Initiate the EMERALD study for DEEs by mid-year 2025.
• Start enrolling patients in the EMBRAVE3 study by mid-year 2025.
• Nominate a development candidate for each of its early stage ASO therapeutic initiatives in 2025.

Key Dates